Sixteen (69.6%) out of the 23 cancers with the −782G>T variant were ER-positive and ERBB2-negative in immunohistochemical stainings (an approximation for the luminal A biological subtype) as compared with 548 (62.8%) out of the 872 cancers that did not harbor this variant (P = 0.510; one of the seven remaining −782G>T cases was ER+/ERBB2+, three ER−/ERBB2+, and three ER−/ERBB2−). This evidence concerns the gene ERBB2 and cancer.